Exelixis, Inc. $EXEL Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. decreased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 20.1% in the third quarter, Holdings Channel.com reports. The firm owned 822,375 shares of the biotechnology company’s stock after selling 207,444 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Exelixis were worth $48,035,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Exelixis during the 2nd quarter valued at approximately $1,581,991,000. Dimensional Fund Advisors LP lifted its position in Exelixis by 0.9% in the first quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock worth $184,391,000 after buying an additional 39,920 shares during the last quarter. Assetmark Inc. lifted its position in Exelixis by 1.7% in the first quarter. Assetmark Inc. now owns 3,388,920 shares of the biotechnology company’s stock worth $145,351,000 after buying an additional 58,149 shares during the last quarter. First Trust Advisors LP lifted its position in Exelixis by 62.0% in the first quarter. First Trust Advisors LP now owns 2,534,992 shares of the biotechnology company’s stock worth $108,726,000 after buying an additional 970,144 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Exelixis by 30.7% during the second quarter. Bank of America Corp DE now owns 2,149,397 shares of the biotechnology company’s stock worth $116,949,000 after buying an additional 504,660 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the transaction, the director directly owned 16,079 shares in the company, valued at $862,799.14. This trade represents a 37.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by insiders.

Exelixis Price Performance

Exelixis stock opened at $65.31 on Friday. The stock has a market cap of $16.18 billion, a price-to-earnings ratio of 20.54, a price-to-earnings-growth ratio of 1.81 and a beta of 0.47. Exelixis, Inc. has a 1 year low of $36.00 and a 1 year high of $65.50. The firm has a 50-day moving average of $57.92 and a two-hundred day moving average of $53.53.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. The business had revenue of $628.69 million for the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 EPS. Research analysts expect that Exelixis, Inc. will post 3.19 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Citizens Jmp boosted their price objective on shares of Exelixis from $55.00 to $65.00 and gave the company a “market outperform” rating in a research report on Monday. BMO Capital Markets initiated coverage on shares of Exelixis in a report on Tuesday, August 18th. They issued a “market perform” rating and a $54.00 target price for the company. Zacks Research raised shares of Exelixis from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 1st. Truist Financial upped their price target on shares of Exelixis from $52.00 to $54.00 and gave the company a “hold” rating in a report on Wednesday, October 7th. Finally, Wells Fargo & Company increased their price objective on shares of Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $51.50.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.